News and Updates

Long time USCACA supporter and advisor, Dr. George Wilding, appointed vice provost for clinical and interdisciplinary research at MD Anderson Cancer Center
----
HOUSTON ― The University of Texas MD Anderson Cancer Center is pleased to announce the appointment of George Wilding, M.D., as vice provost for clinical and interdisciplinary research. Dr. Wilding is a prominent prostate cancer physician-scientist who directed the University of Wisconsin’s Carbone Cancer Center (UWCCC) for 12 years. His appointment at MD Anderson begins Sept. 1.

The USCACA and AFCR are pleased to invite nominations for the USCACA-AFCR 2015 Scholar Awards.

Philadelphia, PA — (May 6, 2015) On April 19, 2015, more than 100 cancer researchers worldwide from academia, industry, and government agencies attended the 7th Annual USCACA Meeting at AACR 2015, organized by a committee consisting of sixteen Executive Members of the USCACA.

AFCR-funded Scientists Discover New Drug Combination to Overcome Chemotherapy Resistance in Ovarian Cancer

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Occam Global is a strategic executive search firm with substantial experience serving entrepreneurial companies in the Healthcare and Technology sectors.

Jan. 21st, 2015, Paris

2014 Chinese Clinical Oncology Advances Awards Announced
From China Medical Tribune

Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).